{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:22:42Z","timestamp":1789564962791,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited monogenic disorders, characterized by a progressive decline in kidney function due in part to the formation of fluid-filled cysts. While there is one FDA-approved therapy, it is associated with potential adverse effects, and all other clinical interventions are largely supportive. Insights into the cellular pathways underlying ADPKD have revealed striking similarities to cancer. Moreover, several drugs originally developed for cancer have shown to ameliorate cyst formation and disease progression in animal models of ADPKD. These observations prompted us to develop a high-throughput screening platform of cancer drugs in a quest to repurpose them for ADPKD. We screened ~8,000 compounds, including compounds with oncological annotations, as well as FDA-approved drugs, and identified 155 that reduced the viability of <jats:italic>Pkd1<\/jats:italic>-null mouse kidney cells with minimal effects on wild-type cells. We found that 109 of these compounds also reduced <jats:italic>in vitro<\/jats:italic> cyst growth of <jats:italic>Pkd1-null<\/jats:italic> cells cultured in a 3D matrix. Moreover, the result of the cyst assay identified therapeutically relevant compounds, including agents that interfere with tubulin dynamics and reduced cyst growth without affecting cell viability. Because it is known that several ADPKD therapies with promising outcomes in animal models failed to be translated to human disease, our platform also incorporated the evaluation of compounds in a panel of primary ADPKD and normal human kidney (NHK) epithelial cells. Although we observed differences in compound response amongst ADPKD and NHK cell preparation, we identified 18 compounds that preferentially affected the viability of most ADPKD cells with minimal effects on NHK cells. Our study identifies attractive candidates for future efficacy studies in advanced pre-clinical models of ADPKD.<\/jats:p>","DOI":"10.1038\/s41598-020-61082-3","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T11:03:15Z","timestamp":1583492595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells"],"prefix":"10.1038","volume":"10","author":[{"given":"Rosita R.","family":"Asawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Danchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Zakharov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ty","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren P.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine F.","family":"Trott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Simeonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"61082_CR1","unstructured":"Harris, P. C. & Torres, V. E. In GeneReviews((R)) (eds Adam, M. P. et al.) (1993)."},{"key":"61082_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres, V. E., Harris, P. C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287\u20131301, https:\/\/doi.org\/10.1016\/S0140-6736(07)60601-1 (2007).","journal-title":"Lancet"},{"key":"61082_CR3","first-page":"669","volume":"98","author":"VE Torres","year":"2007","unstructured":"Torres, V. E., Rossetti, S. & Harris, P. C. Update on autosomal dominant polycystic kidney disease. Minerva Med. 98, 669\u2013691 (2007).","journal-title":"Minerva Med."},{"key":"61082_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrneph.2015.46","volume":"11","author":"T Seeger-Nukpezah","year":"2015","unstructured":"Seeger-Nukpezah, T., Geynisman, D. M., Nikonova, A. S., Benzing, T. & Golemis, E. A. The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat. Rev. Nephrol. 11, 515\u2013534, https:\/\/doi.org\/10.1038\/nrneph.2015.46 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"61082_CR5","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.kint.2017.03.031","volume":"92","author":"VJ Hwang","year":"2017","unstructured":"Hwang, V. J. et al. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. Kidney Int. 92, 922\u2013933, https:\/\/doi.org\/10.1016\/j.kint.2017.03.031 (2017).","journal-title":"Kidney Int."},{"key":"61082_CR6","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar, V. et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl Acad. Sci. USA 108, 2462\u20132467, https:\/\/doi.org\/10.1073\/pnas.1011498108 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61082_CR7","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1681\/ASN.2015030231","volume":"27","author":"M Chiaravalli","year":"2016","unstructured":"Chiaravalli, M. et al. 2-Deoxy-d-Glucose Ameliorates PKD Progression. J. Am. Soc. Nephrol. 27, 1958\u20131969, https:\/\/doi.org\/10.1681\/ASN.2015030231 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"61082_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe, I. et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 19, 488\u2013493, https:\/\/doi.org\/10.1038\/nm.3092 (2013).","journal-title":"Nat. Med."},{"key":"61082_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/368750a0","volume":"368","author":"DD Woo","year":"1994","unstructured":"Woo, D. D., Miao, S. Y., Pelayo, J. C. & Woolf, A. S. Taxol inhibits progression of congenital polycystic kidney disease. Nat. 368, 750\u2013753, https:\/\/doi.org\/10.1038\/368750a0 (1994).","journal-title":"Nat."},{"key":"61082_CR10","unstructured":"NPACT, https:\/\/ncats.nih.gov\/preclinical\/core\/compound\/npact."},{"key":"61082_CR11","doi-asserted-by":"publisher","first-page":"80ps16","DOI":"10.1126\/scitranslmed.3001862","volume":"3","author":"R Huang","year":"2011","unstructured":"Huang, R. et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 3, 80ps16, https:\/\/doi.org\/10.1126\/scitranslmed.3001862 (2011).","journal-title":"Sci. Transl. Med."},{"key":"61082_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ab.2007.04.007","volume":"366","author":"AL Niles","year":"2007","unstructured":"Niles, A. L. et al. A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal. Biochem. 366, 197\u2013206, https:\/\/doi.org\/10.1016\/j.ab.2007.04.007 (2007).","journal-title":"Anal. Biochem."},{"key":"61082_CR13","doi-asserted-by":"publisher","first-page":"11473","DOI":"10.1073\/pnas.0604348103","volume":"103","author":"J Inglese","year":"2006","unstructured":"Inglese, J. et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl Acad. Sci. USA 103, 11473\u201311478, https:\/\/doi.org\/10.1073\/pnas.0604348103 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61082_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1089\/adt.2011.0388","volume":"10","author":"S Huang","year":"2012","unstructured":"Huang, S. & Pang, L. Comparing statistical methods for quantifying drug sensitivity based on in vitro dose-response assays. Assay. Drug. Dev. Technol. 10, 88\u201396, https:\/\/doi.org\/10.1089\/adt.2011.0388 (2012).","journal-title":"Assay. Drug. Dev. Technol."},{"key":"61082_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bcp.12136","volume":"76","author":"MY Chang","year":"2013","unstructured":"Chang, M. Y. & Ong, A. C. New treatments for autosomal dominant polycystic kidney disease. Br. J. Clin. Pharmacol. 76, 524\u2013535, https:\/\/doi.org\/10.1111\/bcp.12136 (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"61082_CR16","unstructured":"https:\/\/clinicaltrials.gov."},{"key":"61082_CR17","doi-asserted-by":"publisher","first-page":"F1179","DOI":"10.1152\/ajprenal.00406.2014","volume":"307","author":"M Tan","year":"2014","unstructured":"Tan, M. et al. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels. Am. J. Physiol. Ren. Physiol 307, F1179\u20131186, https:\/\/doi.org\/10.1152\/ajprenal.00406.2014 (2014).","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"61082_CR18","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1093\/hmg\/ddr338","volume":"20","author":"A Takakura","year":"2011","unstructured":"Takakura, A. et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum. Mol. Genet. 20, 4143\u20134154, https:\/\/doi.org\/10.1093\/hmg\/ddr338 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"61082_CR19","doi-asserted-by":"publisher","first-page":"21819","DOI":"10.1073\/pnas.0911987106","volume":"106","author":"Y Cao","year":"2009","unstructured":"Cao, Y. et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc. Natl Acad. Sci. USA 106, 21819\u201321824, https:\/\/doi.org\/10.1073\/pnas.0911987106 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61082_CR20","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1093\/ndt\/gfr432","volume":"26","author":"B Buchholz","year":"2011","unstructured":"Buchholz, B. et al. The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis. Nephrol. Dial. Transpl. 26, 3458\u20133465, https:\/\/doi.org\/10.1093\/ndt\/gfr432 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"61082_CR21","doi-asserted-by":"publisher","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","volume":"11","author":"M Riwanto","year":"2016","unstructured":"Riwanto, M. et al. Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease. PLoS One 11, e0146654, https:\/\/doi.org\/10.1371\/journal.pone.0146654 (2016).","journal-title":"PLoS One"},{"key":"61082_CR22","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1681\/ASN.2007070828","volume":"19","author":"B Yang","year":"2008","unstructured":"Yang, B., Sonawane, N. D., Zhao, D., Somlo, S. & Verkman, A. S. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 1300\u20131310, https:\/\/doi.org\/10.1681\/ASN.2007070828 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"61082_CR23","doi-asserted-by":"publisher","first-page":"274376","DOI":"10.1155\/2010\/274376","volume":"2010","author":"BL Blazer-Yost","year":"2010","unstructured":"Blazer-Yost, B. L. et al. Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease. PPAR Res. 2010, 274376, https:\/\/doi.org\/10.1155\/2010\/274376 (2010).","journal-title":"PPAR Res."},{"key":"61082_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone II","year":"2003","unstructured":"Gattone, V. H. II, Wang, X., Harris, P. C. & Torres, V. E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9, 1323\u20131326, https:\/\/doi.org\/10.1038\/nm935 (2003).","journal-title":"Nat. Med."},{"key":"61082_CR25","doi-asserted-by":"publisher","first-page":"e0177934","DOI":"10.1371\/journal.pone.0177934","volume":"12","author":"M Kugita","year":"2017","unstructured":"Kugita, M. et al. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease. PLoS One 12, e0177934, https:\/\/doi.org\/10.1371\/journal.pone.0177934 (2017).","journal-title":"PLoS One"},{"key":"61082_CR26","doi-asserted-by":"publisher","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif, G. A. et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl(-) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am. J. Physiol. Ren. Physiol 301, F1005\u20131013, https:\/\/doi.org\/10.1152\/ajprenal.00243.2011 (2011).","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"61082_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","volume":"19","author":"A Pisani","year":"2018","unstructured":"Pisani, A., Riccio, E., Bruzzese, D. & Sabbatini, M. Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? BMC Nephrol. 19, 282, https:\/\/doi.org\/10.1186\/s12882-018-1090-3 (2018).","journal-title":"BMC Nephrol."},{"key":"61082_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","volume":"47","author":"WN Leonhard","year":"2019","unstructured":"Leonhard, W. N. et al. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine 47, 436\u2013445, https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.041 (2019).","journal-title":"EBioMedicine"},{"key":"61082_CR29","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1172\/JCI64401","volume":"123","author":"X Zhou","year":"2013","unstructured":"Zhou, X. et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J. Clin. Invest. 123, 3084\u20133098, https:\/\/doi.org\/10.1172\/JCI64401 (2013).","journal-title":"J. Clin. Invest."},{"key":"61082_CR30","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1073\/pnas.1311846111","volume":"111","author":"LA Mathews Griner","year":"2014","unstructured":"Mathews Griner, L. A. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl Acad. Sci. USA 111, 2349\u20132354, https:\/\/doi.org\/10.1073\/pnas.1311846111 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61082_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep13891","volume":"5","author":"BT Mott","year":"2015","unstructured":"Mott, B. T. et al. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Sci. Rep. 5, 13891, https:\/\/doi.org\/10.1038\/srep13891 (2015).","journal-title":"Sci. Rep."},{"key":"61082_CR32","doi-asserted-by":"publisher","first-page":"12480","DOI":"10.1073\/pnas.1516208112","volume":"112","author":"M Zhang","year":"2015","unstructured":"Zhang, M. et al. Selective targeting of JAK\/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proc. Natl Acad. Sci. USA 112, 12480\u201312485, https:\/\/doi.org\/10.1073\/pnas.1516208112 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61082_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27834-y","volume":"8","author":"NJ Martinez","year":"2018","unstructured":"Martinez, N. J. et al. A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase. Sci. Rep. 8, 9472, https:\/\/doi.org\/10.1038\/s41598-018-27834-y (2018).","journal-title":"Sci. Rep."},{"key":"61082_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2215\/CJN.08880914","volume":"10","author":"A Roy","year":"2015","unstructured":"Roy, A., Al-bataineh, M. M. & Pastor-Soler, N. M. Collecting duct intercalated cell function and regulation. Clin. J. Am. Soc. Nephrol. 10, 305\u2013324, https:\/\/doi.org\/10.2215\/CJN.08880914 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"61082_CR35","doi-asserted-by":"publisher","first-page":"12786","DOI":"10.1073\/pnas.1301904110","volume":"110","author":"T Seeger-Nukpezah","year":"2013","unstructured":"Seeger-Nukpezah, T. et al. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Proc. Natl Acad. Sci. USA 110, 12786\u201312791, https:\/\/doi.org\/10.1073\/pnas.1301904110 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61082_CR36","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.trsl.2014.11.003","volume":"165","author":"WB LaRiviere","year":"2015","unstructured":"LaRiviere, W. B., Irazabal, M. V. & Torres, V. E. Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Transl. Res. 165, 488\u2013498, https:\/\/doi.org\/10.1016\/j.trsl.2014.11.003 (2015).","journal-title":"Transl. Res."},{"key":"61082_CR37","doi-asserted-by":"publisher","first-page":"3982","DOI":"10.1093\/hmg\/ddv136","volume":"24","author":"X Zhou","year":"2015","unstructured":"Zhou, X. et al. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. Hum. Mol. Genet. 24, 3982\u20133993, https:\/\/doi.org\/10.1093\/hmg\/ddv136 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"61082_CR38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/ng.860","volume":"43","author":"SV Fedeles","year":"2011","unstructured":"Fedeles, S. V. et al. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat. Genet. 43, 639\u2013647, https:\/\/doi.org\/10.1038\/ng.860 (2011).","journal-title":"Nat. Genet."},{"key":"61082_CR39","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ki.2008.395","volume":"74","author":"F Wei","year":"2008","unstructured":"Wei, F. et al. Neutrophil gelatinase-associated lipocalin suppresses cyst growth by Pkd1 null cells in vitro and in vivo. Kidney Int. 74, 1310\u20131318, https:\/\/doi.org\/10.1038\/ki.2008.395 (2008).","journal-title":"Kidney Int."},{"key":"61082_CR40","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.kint.2016.10.039","volume":"91","author":"M Fragiadaki","year":"2017","unstructured":"Fragiadaki, M. et al. STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. Kidney Int. 91, 575\u2013586, https:\/\/doi.org\/10.1016\/j.kint.2016.10.039 (2017).","journal-title":"Kidney Int."},{"key":"61082_CR41","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1177\/2472555217716056","volume":"22","author":"TH Booij","year":"2017","unstructured":"Booij, T. H. et al. High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease. SLAS Discov. 22, 974\u2013984, https:\/\/doi.org\/10.1177\/2472555217716056 (2017).","journal-title":"SLAS Discov."},{"key":"61082_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1101\/gad.315127.118","volume":"32","author":"J Cai","year":"2018","unstructured":"Cai, J. et al. A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease. Genes. Dev. 32, 781\u2013793, https:\/\/doi.org\/10.1101\/gad.315127.118 (2018).","journal-title":"Genes. Dev."},{"key":"61082_CR43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00439-013-1378-0","volume":"133","author":"YM Woo","year":"2014","unstructured":"Woo, Y. M. et al. Genome-wide methylation profiling of ADPKD identified epigenetically regulated genes associated with renal cyst development. Hum. Genet. 133, 281\u2013297, https:\/\/doi.org\/10.1007\/s00439-013-1378-0 (2014).","journal-title":"Hum. Genet."},{"key":"61082_CR44","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ndt\/gft521","volume":"29","author":"I Rowe","year":"2014","unstructured":"Rowe, I. & Boletta, A. Defective metabolism in polycystic kidney disease: potential for therapy and open questions. Nephrol. Dial. Transpl. 29, 1480\u20131486, https:\/\/doi.org\/10.1093\/ndt\/gft521 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"61082_CR45","doi-asserted-by":"publisher","unstructured":"Chang, M. Y. & Ong, A. C. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 120, c25\u201334, discussion c35, https:\/\/doi.org\/10.1159\/000334166 (2012).","DOI":"10.1159\/000334166"},{"key":"61082_CR46","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1681\/ASN.2015020132","volume":"27","author":"G Warner","year":"2016","unstructured":"Warner, G. et al. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. J. Am. Soc. Nephrol. 27, 1437\u20131447, https:\/\/doi.org\/10.1681\/ASN.2015020132 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"61082_CR47","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/0272-6386(95)90497-2","volume":"26","author":"RD Gile","year":"1995","unstructured":"Gile, R. D. et al. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am. J. Kidney Dis. 26, 501\u2013507 (1995).","journal-title":"Am. J. Kidney Dis."},{"key":"61082_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/08860220601038892","volume":"29","author":"S Namli","year":"2007","unstructured":"Namli, S. et al. Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren. Fail. 29, 55\u201359, https:\/\/doi.org\/10.1080\/08860220601038892 (2007).","journal-title":"Ren. Fail."},{"key":"61082_CR49","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/hmg\/ddn039","volume":"17","author":"S Shibazaki","year":"2008","unstructured":"Shibazaki, S. et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum. Mol. Genet. 17, 1505\u20131516, https:\/\/doi.org\/10.1093\/hmg\/ddn039 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"61082_CR50","doi-asserted-by":"publisher","first-page":"26329","DOI":"10.1074\/jbc.M601373200","volume":"281","author":"D Joly","year":"2006","unstructured":"Joly, D. et al. The polycystin 1-C-terminal fragment stimulates ERK-dependent spreading of renal epithelial cells. J. Biol. Chem. 281, 26329\u201326339, https:\/\/doi.org\/10.1074\/jbc.M601373200 (2006).","journal-title":"J. Biol. Chem."},{"key":"61082_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ng1076","volume":"33","author":"SM Nauli","year":"2003","unstructured":"Nauli, S. M. et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 33, 129\u2013137, https:\/\/doi.org\/10.1038\/ng1076 (2003).","journal-title":"Nat. Genet."},{"key":"61082_CR52","doi-asserted-by":"publisher","first-page":"F1855","DOI":"10.1152\/ajprenal.00025.2018","volume":"315","author":"JF Trott","year":"2018","unstructured":"Trott, J. F. et al. Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. Am. J. Physiol. Ren. Physiol 315, F1855\u2013F1868, https:\/\/doi.org\/10.1152\/ajprenal.00025.2018 (2018).","journal-title":"Am. J. Physiol. Ren. Physiol"},{"key":"61082_CR53","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.18632\/oncotarget.23462","volume":"9","author":"M Shen","year":"2018","unstructured":"Shen, M. et al. Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. Oncotarget 9, 4758\u20134772, https:\/\/doi.org\/10.18632\/oncotarget.23462 (2018).","journal-title":"Oncotarget"},{"key":"61082_CR54","unstructured":"L., S. R. a. Z. Vol. 2nd edition (Informa Healthcare, 2009)."},{"key":"61082_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 4, 67\u201373, https:\/\/doi.org\/10.1177\/108705719900400206 (1999).","journal-title":"J. Biomol. Screen."},{"key":"61082_CR56","unstructured":"http:\/\/tripod.nih.gov\/curvefit\/."},{"key":"61082_CR57","unstructured":"Oliveros. Venny. An interactive tool for comparing lists with Venn\u2019s diagrams, http:\/\/bioinfogp.cnb.csic.es\/tools\/venny\/index.html (2007)."},{"key":"61082_CR58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/jee\/39.2.269","volume":"39","author":"F Wilcoxon","year":"1946","unstructured":"Wilcoxon, F. Individual comparisons of grouped data by ranking methods. J. Econ. Entomol. 39, 269, https:\/\/doi.org\/10.1093\/jee\/39.2.269 (1946).","journal-title":"J. Econ. Entomol."},{"key":"61082_CR59","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10822-012-9577-7","volume":"26","author":"WA Warr","year":"2012","unstructured":"Warr, W. A. Scientific workflow systems: Pipeline Pilot and KNIME. J. Comput. Aided Mol. Des. 26, 801\u2013804, https:\/\/doi.org\/10.1007\/s10822-012-9577-7 (2012).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"61082_CR60","unstructured":"https:\/\/github.com\/matplotlib\/matplotlib."}],"updated-by":[{"DOI":"10.1038\/s41598-022-21947-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61082-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61082-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61082-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:48:09Z","timestamp":1670312889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61082-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["61082"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-61082-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-022-21947-1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-022-21947-1","URL":"https:\/\/doi.org\/10.1038\/s41598-022-21947-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4203"}}